Comparing the protective effects of ciprofloxacin, moxifloxacin and levofloxacin in mice with lipopolysaccharide-induced acute lung injuries

Heng Ching Huang, Chi Chang Shieh, Wen Liang Yu, Kuo Chen Cheng, Chi Chung Chen, Sheng Tsung Chang, Yin Ching Chuang

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Background and objective: Ciprofloxacin, moxifloxacin and levofloxacin are recognized immunomodulators. Their effects in acute lung injuries have not been tested. This study compared the immunoprotective effects of these agents in mice with lung injuries induced by LPS by measuring the cytokine profiles in the injured lung and the associated mortality. Methods: The development of lung injury and mortality was compared in mice pretreated with either ciprofloxacin, levofloxacin, moxifloxacin or saline (control group) after the intratracheal administration of LPS. BALF and serum were collected at 1, 3 and 6 h to measure the concentrations of tumour necrosis factor-α (TNF-α), IL-1β, IL-6, IL-10 and macrophage inflammatory protein-2 (MIP-2) using enzyme-linked immunoassay. Results: Levels of TNF-α, IL-1β and MIP-2 in the BAL of the ciprofloxacin group were significantly lower compared with those of controls (all P <0.0083) at 3 and 6 h after LPS challenge. There were no significant differences in the levels of these cytokines in the moxifloxacin and levofloxacin groups compared with controls. Overall, the 96-h survival for the mice pretreated with ciprofloxacin, but not for those pretreated with moxifloxacin or levofloxacin, was significantly greater than that of the control animals (P = 0.019). Conclusions: In the setting of LPS-induced lung injuries, ciprofloxacin appears to provide better anti-inflammatory properties and survival benefits than the other fluoroquinolones tested.

Original languageEnglish
Pages (from-to)47-52
Number of pages6
JournalRespirology
Volume13
Issue number1
DOIs
Publication statusPublished - Jan 2008
Externally publishedYes

Fingerprint

Levofloxacin
Acute Lung Injury
Ciprofloxacin
Lipopolysaccharides
Lung Injury
Chemokine CXCL2
Interleukin-1
Tumor Necrosis Factor-alpha
Cytokines
Dimercaprol
Mortality
Fluoroquinolones
Immunologic Factors
Immunoenzyme Techniques
Interleukin-10
Interleukin-6
Anti-Inflammatory Agents
moxifloxacin
Lung
Control Groups

Keywords

  • Acute lung injury
  • Cytokine
  • Fluoroquinolone
  • Lipopolysaccharide

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Comparing the protective effects of ciprofloxacin, moxifloxacin and levofloxacin in mice with lipopolysaccharide-induced acute lung injuries. / Huang, Heng Ching; Shieh, Chi Chang; Yu, Wen Liang; Cheng, Kuo Chen; Chen, Chi Chung; Chang, Sheng Tsung; Chuang, Yin Ching.

In: Respirology, Vol. 13, No. 1, 01.2008, p. 47-52.

Research output: Contribution to journalArticle

Huang, Heng Ching ; Shieh, Chi Chang ; Yu, Wen Liang ; Cheng, Kuo Chen ; Chen, Chi Chung ; Chang, Sheng Tsung ; Chuang, Yin Ching. / Comparing the protective effects of ciprofloxacin, moxifloxacin and levofloxacin in mice with lipopolysaccharide-induced acute lung injuries. In: Respirology. 2008 ; Vol. 13, No. 1. pp. 47-52.
@article{fff61d825fa44f33a4abfffbab3ca3c1,
title = "Comparing the protective effects of ciprofloxacin, moxifloxacin and levofloxacin in mice with lipopolysaccharide-induced acute lung injuries",
abstract = "Background and objective: Ciprofloxacin, moxifloxacin and levofloxacin are recognized immunomodulators. Their effects in acute lung injuries have not been tested. This study compared the immunoprotective effects of these agents in mice with lung injuries induced by LPS by measuring the cytokine profiles in the injured lung and the associated mortality. Methods: The development of lung injury and mortality was compared in mice pretreated with either ciprofloxacin, levofloxacin, moxifloxacin or saline (control group) after the intratracheal administration of LPS. BALF and serum were collected at 1, 3 and 6 h to measure the concentrations of tumour necrosis factor-α (TNF-α), IL-1β, IL-6, IL-10 and macrophage inflammatory protein-2 (MIP-2) using enzyme-linked immunoassay. Results: Levels of TNF-α, IL-1β and MIP-2 in the BAL of the ciprofloxacin group were significantly lower compared with those of controls (all P <0.0083) at 3 and 6 h after LPS challenge. There were no significant differences in the levels of these cytokines in the moxifloxacin and levofloxacin groups compared with controls. Overall, the 96-h survival for the mice pretreated with ciprofloxacin, but not for those pretreated with moxifloxacin or levofloxacin, was significantly greater than that of the control animals (P = 0.019). Conclusions: In the setting of LPS-induced lung injuries, ciprofloxacin appears to provide better anti-inflammatory properties and survival benefits than the other fluoroquinolones tested.",
keywords = "Acute lung injury, Cytokine, Fluoroquinolone, Lipopolysaccharide",
author = "Huang, {Heng Ching} and Shieh, {Chi Chang} and Yu, {Wen Liang} and Cheng, {Kuo Chen} and Chen, {Chi Chung} and Chang, {Sheng Tsung} and Chuang, {Yin Ching}",
year = "2008",
month = "1",
doi = "10.1111/j.1440-1843.2007.01192.x",
language = "English",
volume = "13",
pages = "47--52",
journal = "Respirology",
issn = "1323-7799",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Comparing the protective effects of ciprofloxacin, moxifloxacin and levofloxacin in mice with lipopolysaccharide-induced acute lung injuries

AU - Huang, Heng Ching

AU - Shieh, Chi Chang

AU - Yu, Wen Liang

AU - Cheng, Kuo Chen

AU - Chen, Chi Chung

AU - Chang, Sheng Tsung

AU - Chuang, Yin Ching

PY - 2008/1

Y1 - 2008/1

N2 - Background and objective: Ciprofloxacin, moxifloxacin and levofloxacin are recognized immunomodulators. Their effects in acute lung injuries have not been tested. This study compared the immunoprotective effects of these agents in mice with lung injuries induced by LPS by measuring the cytokine profiles in the injured lung and the associated mortality. Methods: The development of lung injury and mortality was compared in mice pretreated with either ciprofloxacin, levofloxacin, moxifloxacin or saline (control group) after the intratracheal administration of LPS. BALF and serum were collected at 1, 3 and 6 h to measure the concentrations of tumour necrosis factor-α (TNF-α), IL-1β, IL-6, IL-10 and macrophage inflammatory protein-2 (MIP-2) using enzyme-linked immunoassay. Results: Levels of TNF-α, IL-1β and MIP-2 in the BAL of the ciprofloxacin group were significantly lower compared with those of controls (all P <0.0083) at 3 and 6 h after LPS challenge. There were no significant differences in the levels of these cytokines in the moxifloxacin and levofloxacin groups compared with controls. Overall, the 96-h survival for the mice pretreated with ciprofloxacin, but not for those pretreated with moxifloxacin or levofloxacin, was significantly greater than that of the control animals (P = 0.019). Conclusions: In the setting of LPS-induced lung injuries, ciprofloxacin appears to provide better anti-inflammatory properties and survival benefits than the other fluoroquinolones tested.

AB - Background and objective: Ciprofloxacin, moxifloxacin and levofloxacin are recognized immunomodulators. Their effects in acute lung injuries have not been tested. This study compared the immunoprotective effects of these agents in mice with lung injuries induced by LPS by measuring the cytokine profiles in the injured lung and the associated mortality. Methods: The development of lung injury and mortality was compared in mice pretreated with either ciprofloxacin, levofloxacin, moxifloxacin or saline (control group) after the intratracheal administration of LPS. BALF and serum were collected at 1, 3 and 6 h to measure the concentrations of tumour necrosis factor-α (TNF-α), IL-1β, IL-6, IL-10 and macrophage inflammatory protein-2 (MIP-2) using enzyme-linked immunoassay. Results: Levels of TNF-α, IL-1β and MIP-2 in the BAL of the ciprofloxacin group were significantly lower compared with those of controls (all P <0.0083) at 3 and 6 h after LPS challenge. There were no significant differences in the levels of these cytokines in the moxifloxacin and levofloxacin groups compared with controls. Overall, the 96-h survival for the mice pretreated with ciprofloxacin, but not for those pretreated with moxifloxacin or levofloxacin, was significantly greater than that of the control animals (P = 0.019). Conclusions: In the setting of LPS-induced lung injuries, ciprofloxacin appears to provide better anti-inflammatory properties and survival benefits than the other fluoroquinolones tested.

KW - Acute lung injury

KW - Cytokine

KW - Fluoroquinolone

KW - Lipopolysaccharide

UR - http://www.scopus.com/inward/record.url?scp=38049153047&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38049153047&partnerID=8YFLogxK

U2 - 10.1111/j.1440-1843.2007.01192.x

DO - 10.1111/j.1440-1843.2007.01192.x

M3 - Article

C2 - 18197910

AN - SCOPUS:38049153047

VL - 13

SP - 47

EP - 52

JO - Respirology

JF - Respirology

SN - 1323-7799

IS - 1

ER -